At the heart of new antidiabetic agents lies hope for delaying the onset of CVD

+Print Archive
Pathology Update

At the heart of new antidiabetic agents lies hope for delaying the onset of CVD

Virginia
McMillan
JONATHAN SHAW, diabetes
More change is ahead in diabetes treatment, including improving cardiovascular outcomes for more patients, says Australian expert Jonathan Shaw

The fifth and final article in a series from Pathology Update 2019, this year’s conference of the Royal College of Pathologists of Australasia. Virginia McMillan attended as a guest of the college

Glycaemic targets may be relaxed. If a drug will reduce cardiovascular and renal risk, “what is the point of pushing HbA1c from above 7.5 per cent to